A5102713628- Nanoparticle-Based Drug Delivery
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Adenosine and Purinergic Signaling
- Cytomegalovirus and herpesvirus research
- Pancreatic function and diabetes
- Neurological Complications and Syndromes
- Calcium signaling and nucleotide metabolism
- Immune Cell Function and Interaction
AB598 is a CD39 inhibitory antibody being pursued for the treatment of solid tumors in combination with chemotherapy and immunotherapy. metabolizes extracellular adenosine triphosphate (eATP), an alarmin capable promoting antitumor immune responses, into adenosine, immuno-inhibitory metabolite. By inhibiting CD39, consumption eATP reduced, resulting proinflammatory milieu which can activate myeloid cells to promote immunity. The preclinical characterization provides mechanistic rationale...
<div>Abstract<p>AB598 is a CD39 inhibitory antibody being pursued for the treatment of solid tumors in combination with chemotherapy and immunotherapy. metabolizes extracellular adenosine triphosphate (eATP), an alarmin capable promoting antitumor immune responses, into adenosine, immuno-inhibitory metabolite. By inhibiting CD39, consumption eATP reduced, resulting proinflammatory milieu which can activate myeloid cells to promote immunity. The preclinical characterization AB598...
<p>Figure S7</p>
<p>Figure S10</p>
<p>Figure S5</p>
<p>Supplementary Methods</p>
<p>Figure S6</p>
<p>Figure S1</p>
<p>Figure S3</p>
<p>Figure S2</p>
<p>Figure S11</p>
<p>Figure S4</p>
<p>Figure S9</p>
<p>Figure S8</p>
<h3>Background</h3> AB598 inhibits the enzymatic activity of CD39, dominant ATPase in tumor microenvironment (TME). CD39 inhibition allows ATP levels to rise locally, leading activation myeloid cells, increased tumor-specific activated T and enhanced control growth. is potent specific, inhibiting human with sub-nanomolar potency. It effectively but it does not inhibit murine posing a challenge for studying immune-competent syngeneic models. <h3>Methods</h3> The effectiveness combating tumors...
Abstract CD39 (ENTPD1) is an ecto-nucleoside triphosphate diphosphohydrolase expressed widely in the tumor microenvironment (TME) responsible for catalyzing conversion of ATP to AMP. Inhibition enzymatic activity can promote anti-tumor immune responses by increasing immunostimulatory substrate and decreasing formation product AMP, a precursor immunoinhibitory adenosine. inhibition has been shown have effect activating dendritic cells, macrophages, NK cells TME antigen presentation...